These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25681308)

  • 41. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
    Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
    Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
    Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
    Niwińska A; Tacikowska M; Murawska M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
    Fabi A; Di Benedetto A; Metro G; Perracchio L; Nisticò C; Di Filippo F; Ercolani C; Ferretti G; Melucci E; Buglioni S; Sperduti I; Papaldo P; Cognetti F; Mottolese M
    Clin Cancer Res; 2011 Apr; 17(7):2055-64. PubMed ID: 21307144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
    Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
    J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
    Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
    Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
    Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Kim JS; Kim K; Jung W; Shin KH; Im SA; Kim HJ; Kim YB; Chang JS; Kim JH; Choi DH; Park YH; Kim DY; Kim TH; Choi BO; Lee SW; Kim S; Kwon J; Kang KM; Chung WK; Kim KS; Yoon WS; Kim JH; Cha J; Oh YK; Kim IA
    Breast Cancer Res Treat; 2021 Apr; 186(2):453-462. PubMed ID: 33392845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer.
    Sun B; Huang Z; Wu S; Ding L; Shen G; Cha L; Wang J; Song S
    Oncotarget; 2016 Nov; 7(45):74006-74014. PubMed ID: 27659537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
    Chen PC; Yeh YM; Chu CT; Su PF; Chiu PH; Lin BW; Chen SH; Lin PC; Lee CT; Chen HHW; Chen CC
    Eur J Cancer; 2023 Mar; 181():62-69. PubMed ID: 36640475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between brain metastasis and HER2 expression status in gastric cancer.
    Lai MY; Guan WL; Yang J; Sun YT; Lu SX; Yang LQ; Yang DJ; Qiu MZ
    Clin Transl Oncol; 2024 Mar; 26(3):765-773. PubMed ID: 37620706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of HER2 in brain metastasis of breast cancer: a systematic review and meta-analysis.
    Hedayatizadeh-Omran A; Rafiei A; Alizadeh-Navaei R; Tehrani M; Valadan R; Moradzadeh K; Panbechi M; Taghavi SM
    Asian Pac J Cancer Prev; 2015; 16(4):1431-4. PubMed ID: 25743811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.